AVDL Avadel Pharmaceuticals plc

10.11
-0.05  -0%
Previous Close 10.16
Open 10.13
Price To book 5.29
Market Cap 405250837
Shares 40,084,158
Volume 130,029
Short Ratio 2.57
Av. Daily Volume 184,791

SEC filingsSee all SEC filings

  1. 8-K - Current report 171104947
  2. 8-K - Current report 171079256
  3. 8-K/A [Amend] - Current report 171072497
  4. 8-K/A [Amend] - Current report 171072429
  5. 8-K - Current report 171070090

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved June 3, 2013.
Bloxiverz (neostigmine methylsulfate)
Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery
Announced approval May 2 2016
Akovaz
Hypotension
Phase 3 SPA agreed on - October 2016. Initiation of dosing announced December 16, 2016.
Micropump Sodium Oxybate
Excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy
Approved June 30 2014.
VAZCULEP (phenylephrine hydrochloride)
Clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia
Approved Jun 3 2013
Bloxiverz (neostigmine methylsulfate)
Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery

SEC Filings

  1. 8-K - Current report 171104947
  2. 8-K - Current report 171079256
  3. 8-K/A [Amend] - Current report 171072497
  4. 8-K/A [Amend] - Current report 171072429
  5. 8-K - Current report 171070090
  6. 8-K - Current report 171069580
  7. 8-K - Current report 171043512
  8. 8-K - Current report 171039098
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018783
  10. 8-K - Current report 171013748